Stay updated on Ravulizumab Study in LN/IgAN Clinical Trial

Sign up to get notified when there's something new on the Ravulizumab Study in LN/IgAN Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ravulizumab Study in LN/IgAN Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A journal article analyzing urinary biomarkers from the SANCTUARY trial and their implications for IgA nephropathy and ravulizumab has been added to the study’s publications.
    Difference
    0.0%
    Check dated 2026-11-15T13:50:45.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The ravulizumab trial record for lupus nephritis and IgA nephropathy is available, with study details and results information; it is marked terminated and no longer recruiting participants.
    Difference
    88%
    Check dated 2026-11-08T13:43:47.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0 on the page displaying a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T14:54:29.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    A site-wide NIH notice was added above the page, announcing a transition in terminology from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-25T15:42:22.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-18T22:17:30.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.0 to v3.7.1. The study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T22:14:40.000Z thumbnail image

Stay in the know with updates to Ravulizumab Study in LN/IgAN Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ravulizumab Study in LN/IgAN Clinical Trial page.